Search General Info
Search Education
Search Partnering Companies
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
Ethris mission is to redefine mRNA medicines through best-in-industry delivery, stability,and nebulization technology.
Ethris is developing mRNA-based therapeutics and vaccines to treat patients with (rare) respiratory disorders and infectious diseases.
Its novel, proprietary technology platform consisting of SNIM RNA , SNaP LNP and Stabilizer preventing LNP aggregation which affords multi-route, multi-cargo delivery options for intramuscular, inhaled or nasal administration and suitable for several genetic medicine payloads including mRNA and gene editing technologies such as CRISPR/Cas.
Platform capabilities overcome key obstacles of currently available mRNA and LNP technology through superior stability removing ultra-cold chain requirements, potent delivery through proprietary SNaP LNP, best-in-class nebulization and improved tolerability through SNIM RNA.
Ethris is developing mRNA-based therapeutics and vaccines to treat patients with (rare) respiratory disorders and infectious diseases.
Its novel, proprietary technology platform consisting of SNIM RNA , SNaP LNP and Stabilizer preventing LNP aggregation which affords multi-route, multi-cargo delivery options for intramuscular, inhaled or nasal administration and suitable for several genetic medicine payloads including mRNA and gene editing technologies such as CRISPR/Cas.
Platform capabilities overcome key obstacles of currently available mRNA and LNP technology through superior stability removing ultra-cold chain requirements, potent delivery through proprietary SNaP LNP, best-in-class nebulization and improved tolerability through SNIM RNA.
![](https://www.abstractscorecard.com/uploads/Tasks/upload/20525/EOISBJNL-1541439-1-JPG(1).png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Bavaria
Company HQ Country:
Germany
Year Founded:
2009
Main Therapeutic Focus:
Respiratory
Lead Product in Development:
Lead indications in rare respiratory diseases including, primary ciliary dyskinesia (PCD) and pulmonary alveolar proteinosis (PAP), entering the clinic in 2024 and 2025 respectively.
Infectious diseases: Viral prophylaxis and virus induced asthma exacerbations (CTA Q2/2023), and vaccines (i.m. and nasal platform) including a CEPI funded pan beta-coronavirus vaccine.
Development Phase of Primary Product:
NDA Preparation/In Review
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1-3
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-RudolphC.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved